Andrew Combs - Mar 31, 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role: EVP, Head of Chemistry
Signature: /s/ Laurent Chardonnet, as Attorney-in-Fact
Stock symbol: PRLD
Transactions as of: Mar 31, 2022
Transactions value $: $68,157
Form type: 4
Date filed: 4/4/2022, 05:08 PM
Previous filing: Feb 17, 2022
Next filing: Feb 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRLD	Common Stock	Options Exercise	$68.2K	+36.1K	+13.44%	$1.89	304K	Mar 31, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRLD	Employee Stock Option (right to buy)	Options Exercise	$0	-36.1K	-41.71%	$0.00	50.4K	Apr 1, 2022	Common Stock	36.1K	$1.89	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
F2	The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.